SenseCheQ: Home-based Nerve Function Self-Assessment using Autonomous Quantitative Sensory Testing

The paper introduces SenseCheQ, a home-based autonomous quantitative sensory testing system that enables patients undergoing chemotherapy to self-monitor nerve function with clinical-grade reliability, facilitating early detection of neuropathy through the identification of sub-clinical changes.

The Gist

The Big Problem: The "Silent Thief" of Cancer Treatment

Imagine you are taking a powerful medicine to fight cancer (chemotherapy). It's a life-saver, but it has a nasty side effect: it can damage your nerves. This is called Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Think of your nerves like the electrical wiring in your house. Chemotherapy is like a storm that can chew through the insulation.

• The Issue: About 30% of people end up with permanent damage. They feel numbness, tingling, or pain in their hands and feet.
• The Current Fix: Right now, doctors mostly wait for the patient to say, "Ouch, my hands feel weird." By then, the wiring might already be fried. The only way to stop the damage is to stop or lower the chemotherapy dose, but that might mean the cancer isn't treated as well.
• The Goal: We need to catch the damage before it becomes a big problem, so doctors can tweak the medicine just enough to save the nerves without hurting the cancer treatment.

The Solution: A "Smart Doorbell" for Your Nerves

The researchers built a device called SenseCheQ. Think of it as a high-tech, self-checking doorbell for your nervous system that you can use in your own living room.

Currently, checking your nerves requires a trip to a fancy lab with a specialist, expensive equipment, and a lot of time. SenseCheQ changes the game by letting patients do it themselves at home, like checking their blood pressure.

How Does It Work? (The "Magic Pad")

The device looks like a small box with a flat pad on top. You rest your thumb on it. It does three things to test your nerves:

1. The Vibration Test (The "Tickle"): It vibrates your thumb. You press a button the moment you feel the tickle. This checks your "big wire" nerves (Aβ fibers).
2. The Temperature Test (The "Ice & Fire"): It cools down and heats up your thumb. You press the button the moment you feel the change. This checks your "small wire" nerves (Aδ and C fibers) that handle pain and temperature.

The Secret Sauce: Calibration
Here is the clever part. If you press down too hard on the pad, the vibration feels weaker. If your hand is cold, you might not feel the vibration as well.

• The Analogy: Imagine trying to listen to a song on a radio while someone is constantly turning the volume knob up and down. You'd never know if the song got quieter or if the volume just got turned down.
• The Fix: Before the real test, SenseCheQ does a quick "sound check." It vibrates your thumb while a tiny sensor inside measures exactly how much you are pressing down. It then auto-adjusts the volume so the vibration is perfect every single time, no matter how hard you press or how cold your room is. It's like a smart thermostat that keeps your house at the perfect temperature regardless of the weather outside.

What Did They Find?

The team tested this on healthy people and then on three brave cancer patients undergoing chemotherapy.

• Reliability: When healthy people used it at home, the results were consistent. It worked just as well as the big, expensive lab machines.
• The "Early Warning System":
  • Patient 1: Had no symptoms. The device showed no changes. (Good news!)
  • Patient 2: Started feeling tingling in their fingers. The device showed a massive spike in the vibration threshold before the tingling got really bad. It caught the "frying wires" early.
  • Patient 3: Had a rollercoaster of symptoms. The device tracked the ups and downs perfectly, showing that their nerves got worse after a dose of chemo and recovered a bit before the next one.

Why This Matters

Think of SenseCheQ as a smoke detector for your nerves.

• Old Way: You wait until the house is on fire (severe pain/numbness) to call the fire department (change the chemo).
• New Way: The smoke detector (SenseCheQ) beeps the moment you see a tiny wisp of smoke. The doctor can then adjust the heat (chemo dose) just enough to stop the fire without turning off the whole house.

The Bottom Line

This paper introduces a cheap, easy-to-use, self-calibrating device that lets patients monitor their nerve health at home. It's accurate, reliable, and could help doctors prevent permanent nerve damage, ensuring patients get the full power of their cancer treatment without losing their quality of life. It turns a complex medical test into something as simple as pressing a button on a kitchen counter.

Technical Summary

1. Problem Statement

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a debilitating side effect of cancer treatment (e.g., taxanes, platin compounds) affecting up to 70% of patients acutely and 30% chronically. Currently, there are no effective preventive or remedial therapies other than modifying or stopping chemotherapy.

• The Gap: Early detection is critical to prevent irreversible nerve damage, but current clinical assessments rely on subjective patient reporting or insensitive bedside tests.
• Limitations of Existing Tools: Formal Quantitative Sensory Testing (QST) is objective but requires trained personnel, expensive equipment, controlled environments, and patient travel to clinics. This prevents the high-frequency longitudinal monitoring necessary to catch early, sub-clinical changes.
• The Challenge: There is a need for a low-cost, reliable, self-administered device capable of performing rigorous QST in uncontrolled home environments to enable early intervention.

2. Methodology

The authors developed SenseCheQ, an autonomous, integrated sensory testing platform designed for home use.

A. Device Design & Hardware

• Form Factor: A "SensePad" device where the user places their hand (specifically the thenar eminence).
• Stimuli:
  • Thermal: A Peltier (thermoelectric) module with a conductive faceplate for heating and cooling.
  • Mechanical: A Linear Resonant Actuator (LRA) for vibration.
  • Integration: Unique capability to apply thermal and vibration stimuli simultaneously to the same skin area.
• Control System:
  • Master: Raspberry Pi 4 (GUI, data logging).
  • Real-time Control: Two Arduino microcontrollers (MKR Zero for thermal, Nano ESP32 for haptics) to ensure precise timing and safety.
• Safety: Triple-layer thermal safety (software cut-out at 43°C, hardware comparator cut-out at 45°C, and a 2A fuse) to prevent burns in patients with sensory loss.
• Interface: Physical haptic buttons (avoiding touchscreens which may be difficult for patients with neuropathy or fatigue) and a 5" display.

B. Key Technical Innovations

1. Haptic Calibration Routine:
   • Problem: Vibration amplitude varies based on user pressure and skin coupling.
   • Solution: Before each test, a stepped vibration ramp is delivered. An embedded 3-axis accelerometer measures the actual stack movement. A regression model calculates the relationship between drive voltage and actual amplitude, allowing the system to dynamically adjust drive values to hit target amplitudes regardless of user pressure.
   • Result: Reduced variance in delivered vibration by 78.74%.
2. Thermal Clamping:
   • Problem: Skin temperature affects vibration sensitivity.
   • Solution: The device clamps skin temperature to a baseline of 32°C before and during vibration testing to eliminate thermal variance.
3. Protocol:
   • Measures Vibration Detection Threshold (VDT), Cold Detection Threshold (CDT), and Warm Detection Threshold (WDT).
   • Each parameter is measured four times per session.

C. Study Design

• Healthy Participant Study (N=30): Conducted in a clinic and three subsequent home sessions to assess test-retest reliability and the impact of thermal clamping.
• Patient Case Studies (N=3): Three breast cancer patients undergoing neurotoxic chemotherapy (Paclitaxel, Docetaxel/Carboplatin). They performed unsupervised weekly/bi-weekly home testing alongside periodic lab-based QST.

3. Key Results

A. Reliability and Performance (Healthy Participants)

• Test-Retest Reliability:
  • VDT: High reliability (Spearman's $\rho$ = 0.75, ICC = 0.66). Mean absolute difference between sessions was 0.16 µm.
  • CDT: High reliability (Spearman's $\rho$ = 0.79, ICC = 0.69). Mean absolute difference was 0.38°C.
  • WDT: Moderate reliability (ICC = 0.32), consistent with literature showing thermal thresholds are inherently more variable than mechanical ones.
• Impact of Calibration: The haptic calibration routine significantly reduced within-participant variance ($p < 0.001$).
• Impact of Thermal Clamping: Sessions where skin temperature was not clamped showed significantly higher variance in VDT. Cooler skin correlated with higher (worse) VDTs, confirming the necessity of thermal control for vibration testing.

B. Patient Case Studies

• Patient 1 (No Symptoms): Showed stable sensory function throughout treatment; SenseCheQ data matched lab results and patient reports (no CIPN).
• Patient 2 (Developed Symptoms): Reported paraesthesia (tingling) coinciding with a doubling of VDT and increased variance in WDT. SenseCheQ detected these sub-clinical changes before they became severe.
• Patient 3 (Cyclical Symptoms): Reported tingling after infusions that subsided before the next. SenseCheQ detected a cyclical pattern in VDT (worsening 2 weeks post-infusion) that would have been missed if testing only occurred immediately before infusions.

C. Cost and Usability

• Cost: Component cost is approximately £500, an order of magnitude cheaper than commercial QST systems.
• Usability: Patients reported the device was intuitive, easy to use, and did not require technical expertise.

4. Significance and Contributions

• First-of-its-Kind Platform: SenseCheQ is the first device to enable fully autonomous, self-administered QST in the home setting with clinical-grade reliability.
• Sub-Clinical Detection: The device successfully detected nerve function changes (sub-micron vibration changes and fraction-of-a-degree thermal changes) that precede clinical symptoms, offering a window for early therapeutic intervention.
• Engineering Solutions to Biological Variance: The novel combination of active haptic calibration and thermal clamping effectively neutralizes environmental and user-induced noise, making home testing viable.
• Scalability: The low cost and ease of use suggest this platform could be widely deployed for monitoring CIPN, diabetic neuropathy, and as a surrogate biomarker for drug development trials.
• Clinical Impact: By enabling frequent monitoring, SenseCheQ could allow oncologists to modify chemotherapy regimens earlier, potentially preventing permanent nerve damage without unnecessarily compromising cancer treatment efficacy.

Conclusion

The paper demonstrates that SenseCheQ is a robust, reliable, and cost-effective solution for home-based nerve function monitoring. By overcoming the technical challenges of environmental variance through innovative calibration and thermal control, it bridges the gap between rigorous laboratory QST and practical, longitudinal clinical care.